EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase

Masaomi Nangaku, Ichiro Kojima, Tetsuhiro Tanaka, Takamoto Ohse, Hideki Kato, Toshiro Fujita

Recent Patents on Cardiovascular Drug Discovery · 2006

DOI: 10.2174/157489006777442522 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on Cardiovascular Drug Discovery, 2006. Verfasst von Masaomi Nangaku und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. mnangaku-tky@umin.a…. Die Arbeit wurde bisher 31-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tissue hypoxia occurs when local metabolism is disturbed by an imbalance between oxygen supply and consumption. This condition can lead to a variety of serious ischemic disorders, including a number of important cardiovascular diseases. In the search for therapeutic approaches, focused modalities which specifically target hypoxia have been particularly sought. These efforts would profit from the ability to utilize the mechanisms by which cells adjust to hypoxic conditions. At the center of the cellular response to hypoxia is hypoxia-inducible factor, HIF. This factor is composed of two subunits, an oxygen-sensitive HIF-alpha subunit and a constitutively expressed HIF-beta subunit. Intracellular accumulation of HIF induces the coordinated expression of a number of adaptive genes against hypoxic insult. Because activation of HIF is a promising therapeutic modality for ischemic cardiovascular disease, recent studies have focused on the development of HIF stimulators. HIF levels are regulated by prolyl hydroxylation and asparaginyl hydroxylation of the HIF-alpha subunit. To date, a single HIF asparaginyl hydroxylase has been identified, factor inhibiting HIF (FIH), whereas the mammalian genome encodes three closely related proteins that have HIF prolyl hydroxylase activity, PHD1, PHD2 and PHD3. Recent patents have disclosed methods for identifying modulators of HIF or PHD as well as novel compounds with properties of HIF modulation or prolyl hydroxylase inhibition. This review highlights the identification of novel HIF stabilizers as specific molecularly targeted therapies against cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsCardiovascular DiseasesEnzyme InhibitorsHumansHypoxiaHypoxia-Inducible Factor 1Procollagen-Proline Dioxygenase

Substanzen

Enzyme InhibitorsHypoxia-Inducible Factor 1Procollagen-Proline Dioxygenase

Autor:innen und Institutionen

  • Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. mnangaku-tky@umin.ac.jp

Zitieren

APA

Nangaku, M., Kojima, I., Tanaka, T., Ohse, T., Kato, H., & Fujita, T. (2006). Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase. Recent Patents on Cardiovascular Drug Discovery. https://doi.org/10.2174/157489006777442522

Vancouver

Nangaku M, Kojima I, Tanaka T, Ohse T, Kato H, Fujita T. Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase. Recent Patents on Cardiovascular Drug Discovery. 2006. doi:10.2174/157489006777442522

BibTeX
@article{Nangaku2006,
  author = {Nangaku, Masaomi and Kojima, Ichiro and Tanaka, Tetsuhiro and Ohse, Takamoto and Kato, Hideki and Fujita, Toshiro},
  title = {Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase},
  journal = {Recent Patents on Cardiovascular Drug Discovery},
  year = {2006},
  doi = {10.2174/157489006777442522}
}
Kostenlos starten →